Monotherapy with bulevirtide well tolerated in patients with chronic hepatitis delta

Monotherapy with bulevirtide well tolerated in patients with chronic hepatitis delta

Monotherapy with bulevirtide among patients with compensated hepatitis delta was safe and well tolerated, according to a presentation at the International Liver Congress.“Safety and efficacy were confirmed,” Heiner Wedemeyer, MD, professor and chairman of the clinic for gastroenterology, hepatology and endocrinology, Hannover Medical Hospital, Germany, said during his presentation. “However, these were only 24-week interim data and only a very small number of patients actually had completely undetectable [hepatitis D virus (HDV)] RNA. There was no effect on HBsAg.”InRead More

Share on facebook
Share on twitter
Share on linkedin